Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes

References

• DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795.
   PubMed Web of Science ®Google Scholar
• Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–54.
   PubMed Web of Science ®Google Scholar
• Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819‐837.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5‐21.
   PubMedGoogle Scholar
• Nauck MA, Meier JJ. GIP and GLP-1: stepsiblings rather than monozygotic twins within the incretin family. Diabetes. 2019;68:897‐900.
   PubMed Web of Science ®Google Scholar
• Gasbjerg LS, Bergmann NC, Stensen S, et al. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides. 2020;125:170–183.
   Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696‐1705.
   PubMed Web of Science ®Google Scholar
• Holst JJ. Incretin therapy for diabetes mellitus type 2. Curr Opin Endocrinol Diabetes Obes. 2020;27:2‐10.
   PubMedGoogle Scholar
• Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72‐130.
   Web of Science ®Google Scholar
• Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91(1):301‐307.
   PubMed Web of Science ®Google Scholar
• T. V, T. K, Madsbad M, et al. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia. 2002;45(8):1111–1119.
   PubMed Web of Science ®Google Scholar
• Investor.lilly.com [internet]. Eli Lilly and company, Indianapolis, IN. Amylin and Lilly announce FDA approval of BYETTA(TM) (Exenatide) injection; April 29, 2005. cited 2020 Sept 20. Available from https://investor.lilly.com/news-releases/news-release-details/amylin-and-lilly-announce-fda-approval-byettatm-exenatide
   Google Scholar
• Zaccardi F, Htike ZZ, Webb DR, et al. Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis. Ann Intern Med. 2016;164:102‐113.
   PubMed Web of Science ®Google Scholar
• Chudleigh RA, Platts J, Bain SC. Comparative effectiveness of long-acting GLP-1 receptor agonists in type 2 diabetes: a short review on the emerging data. Diabetes Metab Syndr Obes. 2020;13:433‐438.
   PubMed Web of Science ®Google Scholar
• Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776‐785.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019;45:409‐418.
   PubMed Web of Science ®Google Scholar
• Frias JP. Safety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes. J Fam Pract. 2018;67(6suppl):S25‐S34.
   PubMedGoogle Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetologia. 2018;61:2461‐2498.
   Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2019 [2020];43:487‐493.
   Web of Science ®Google Scholar
• Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American association of clinical endocrinologist and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary. Endocr Pract. 2020;26:107‐139.
   PubMedGoogle Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019;41:255–323.
   Web of Science ®Google Scholar
• Capozzi ME, DiMarchi RD, Tschöp MH, et al. Targeting the incretin/glucagon system with triagonists to treat diabetes. Endocr Rev. 2018;39:719‐738.
   PubMed Web of Science ®Google Scholar
• Knerr PJ, Mowery SA, Finan B, et al. Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates. Peptides. 2020;125:170–225.
   Web of Science ®Google Scholar
• Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14.
   PubMed Web of Science ®Google Scholar
• Ohwaki K, Furihata K, Mimura H, et al. Effect of tirzepatide, a dual GIP and GLP-1 receptor agonist, on glycemic control and body weight in Japanese patients with T2DM. Diabetes. 2019 Jun;68(Supplement 1):1024-P. Presented at 79th Scientific Sessions of the American Diabetes Association, San Francisco, CA. June 7-11, 2019. Poster 1024-P
   Google Scholar
• Investor.lilly.com [internet]. Eli Lilly and Company, Indianapolis, IN. 2020 business results; April 23, 2020. Slide 47 of 57. Accessed 2020 Sept 20. Available from https://investor.lilly.com/static-files/68230d7a-ba20-43dc-979b-fea529a5e6c4
   Google Scholar
• Urva S, Quinlan T, Landry J, et al. Renal impairment has no impact on the clinical pharmacokinetics of tirzepatide. Diabetes. 2020 June;69Supplement 1: Presented online at 80th Scientific Sessions of the American Diabetes Association 2020 Jun 12-16 Poster 940-P doi:10.2337/db20-971-P
   Google Scholar
• Lund A, Vilsbøll T, Bagger JI, et al. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab. 2011;300:E1038–E1046.
   PubMed Web of Science ®Google Scholar
• El K, Campbell JE. The role of GIP in α-cells and glucagon secretion. Peptides. 2020;125:170213.
   PubMed Web of Science ®Google Scholar
• Finan B, Müller TD, Clemmensen C, et al. Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol Med. 2016;22:359‐376.
   PubMed Web of Science ®Google Scholar
• Killion EA, Lu SC, Fort M, et al. Glucose-dependent insulinotropic polypeptide receptor therapies for the treatment of obesity, do agonists = antagonists? Endocr Rev. 2020;41:bnz002.
   PubMed Web of Science ®Google Scholar
• Bergmann NC, Gasbjerg LS, Heimbürger SM, et al. No acute effects of exogenous glucose-dependent insulinotropic polypeptide on energy intake, appetite, or energy expenditure when added to treatment with a long-acting glucagon-like peptide 1 receptor agonist in men with type 2 diabetes. Diabetes Care. 2020;43:588‐596.
   PubMed Web of Science ®Google Scholar
• Mroz PA, Finan B, Gelfanov V, et al. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Mol Metab. 2019;20:51‐62.
   PubMed Web of Science ®Google Scholar
• Højberg PV, Vilsbøll T, Rabøl R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52:199‐207.
   PubMed Web of Science ®Google Scholar
• Mathiesen DS, Bagger JI, Bergmann NC, et al. The effects of dual GLP-1/GIP receptor agonism on glucagon secretion - a review. Int J Mol Sci. 2019;20:4092.
   Web of Science ®Google Scholar
• Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392:2180‐2193.
   PubMedGoogle Scholar
• Mohammad S, Patel RT, Bruno J, et al. A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity. Mol Cell Biol. 2014;34:3618‐3629.
   PubMed Web of Science ®Google Scholar
• Adriaenssens AE, Gribble FM, Reimann F. The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system. Peptides. 2020;125:170–194.
   Web of Science ®Google Scholar
• Adriaenssens AE, Biggs EK, Darwish T, et al. Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab. 2019;30:987‐996.e6.
   PubMed Web of Science ®Google Scholar
• Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31:410‐421.
   PubMed Web of Science ®Google Scholar
• Holst JJ, Rosenkilde MM. GIP as a therapeutic target in diabetes and obesity: Insight from incretin co-agonists. J Clin Endocrinol Metab. 2020;105(8):e2710–e2716.
   Google Scholar
• Ohwaki K, Furihata K, Oura T, et al. Effects of tirzepatide on meal intake and appetite in Japanese patients with type 2 diabetes. Diabetes. 2020 Jun;69Supplement 1 :969-P. Presented at the 80th Scientific Sessions of the American Diabetes Association 2020 Jun 12-16 Poster 969-P
   Google Scholar
• ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT04235959, A study of tirzepatide in Chinese participants with type 2 diabetes mellitus; 2019 Nov 19 [ cited 2020 Jun 14]; [about 6 screens]. cited 2020 Sept 20. Available from https://clinicaltrials.gov/ct2/show/NCT04235959
   Google Scholar
• Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22:938‐946.
   Web of Science ®Google Scholar
• Thomas MK, Nikooienejad A, Bray R, et al. Tirzepatide, a dual GIP and GLP-1 receptor agonist, improved markers of beta-cell function and insulin sensitivity in type 2 diabetes patients. Diabetes. 2019 Jun;68(Supplement 1):980-P. Presented at 79th Scientific Sessions of the American Diabetes Association, San Francisco, CA. June 7-11, 2019. Poster 980-P
   PubMedGoogle Scholar
• Wilson JM, Nikooienejad A, Bowsman LM, et al. The dual GIP/GLP-1 receptor agonist tirzepatide improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Presented at 55th European Association for the Study of Diabetes Annual Meeting, Barcelona, Spain. 18 September 2019. e-Poster 1161.
   Google Scholar
• Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52:453‐462.
   Web of Science ®Google Scholar
• Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43:1352‐1355.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT04166773, A study of tirzepatide (LY3298176) in participants with nonalcoholic steatohepatitis (NASH) (SYNERGY-NASH); 2019 Nov 19 [ cited 2020 Jun 14]; [about 6 screens]. Accessed 2020 Sept 20. Available from https://clinicaltrials.gov/ct2/show/NCT04166773
   Google Scholar
• Investor.lilly.com [internet]. Eli Lilly and Company, Indianapolis, IN. First patient dose delivered for Lilly’s tirzepatide cardiovascular outcomes trial; June 9, 2020. Accessed 2020 Sept 20. Available from https://investor.lilly.com/news-releases/news-release-details/first-patient-dose-delivered-lillys-tirzepatide-cardiovascular
   Google Scholar
• ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT04255433, A study of tirzepatide (LY3298176) compared with dulaglutide on major cardiovascular events in participants with type 2 diabetes (SURPASS-CVOT); 2020 Feb 05 [ cited 2020 Jun 14]; [about 6 screens]. cited 2020 Sept 20. Available from https://clinicaltrials.gov/ct2/show/NCT04255433
   Google Scholar
• Investor.lilly.com [internet]. Eli Lilly and company, Indianapolis, IN. Diabetes 2019 business update; June 10, 2019. Accessed 2020 Sept 20. Slide 21 of 27. Available from https://investor.lilly.com/events/event-details/lilly-diabetes-update
   Google Scholar
• Lilly.com [internet]. Eli Lilly and Company, Indianapolis, IN. 2019 Integrated summary report. Page 7 of 42. Accessed 2020 Sept 20. Available from https://www.lilly.com/policies-reports/integrated-summary-report
   Google Scholar
• ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT04184622, A study of tirzepatide (LY3298176) in participants with obesity or overweight (SURMOUNT-1); 2019 Dec 03 [ cited 2020 Jun 14]; [about 6 screens]. Accessed 2020 Sept 20. Available from https://clinicaltrials.gov/ct2/show/NCT04184622
   Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275‐286.
   PubMed Web of Science ®Google Scholar
• Frias JP, Nevarez Ruiz L, Li YG, et al. Efficacy and safety of higher dulaglutide doses (3.0 MG and 4.5 MG) when added to metformin in patients with type 2 diabetes: A phase 3, randomized, double-blind, parallel arm study (AWARD-11). J Endocr Soc. 2020;4Supplement 1 Presented online at the 2020 Endocrine Society Annual Meeting 2020 Jun 8-12. 2020 Jun 8-22. OR26-08 doi:10.1210/jendso/bvaa046.2057
   Google Scholar
• Frias JP, Bonora E, Nevarez Ruiz LA, et al. Efficacy and safety of dulaglutide 3mg and 4.5mg vs. Dulaglutide 1.5mg: 52-week results from AWARD-11. Diabetes. 2020 Jun;69Supplement 1: Presented online at 80th Scientific Sessions of the American Diabetes Association Jun 12-16. 2020. Oral 357-OR doi:10.2337/db20-357-OR
   Google Scholar
• Investor.lilly.com [internet]. Eli Lilly and company, Indianapolis, IN. FDA approves additional doses of Trulicity® (dulaglutide) for the treatment of type 2 diabetes; September 3, 2020. Accessed 2020 Sept 20. Available from https://investor.lilly.com/news-releases/news-release-details/fda-approves-additional-doses-trulicityr-dulaglutide-treatment
   Google Scholar
• ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03989232, A research study to compare two doses of semaglutide taken once weekly in people with type 2 diabetes (SUSTAIN FORTE); 2019 Jun 18 [ cited 2020 Jun 14]; [about 6 screens]. Accessed 2020 Sept 20. Available from https://clinicaltrials.gov/ct2/show/NCT03989232
   Google Scholar
• ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03987919, A study of tirzepatide (LY3298176) versus semaglutide once weekly as add-on therapy to metformin in participants with type 2 diabetes (SURPASS-2); 2019 Jun 17 [ cited 2020 Jun 14]; [about 6 screens]. Accessed 2020 Jun 20. Available from https://clinicaltrials.gov/ct2/show/NCT03987919
   Google Scholar
• Dardano A, Miccoli R, Bianchi C, et al. Invited review. Series: implications of the recent CVOTs in type 2 diabetes: which patients for GLP-1RA or SGLT-2 inhibitor? Diabetes Res Clin Pract. 2020;162:108112.
   PubMed Web of Science ®Google Scholar
• Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4:1004‐1016.
   PubMed Web of Science ®Google Scholar
• Ludvik B, Frías JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6:370‐381.
   PubMed Web of Science ®Google Scholar
• Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7:356‐367.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab. 2017;19:1353‐1362.
   Web of Science ®Google Scholar
• Strain WD, Hope SV, Green A, et al. Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty. A national collaborative stakeholder initiative. Diabet Med. 2018;35:838‐845.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17:83.
   PubMed Web of Science ®Google Scholar
• Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260‐272.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention [Internet]. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. dept of health and human services; 2020. Accessed 2020 Sept 20. Available from https://www.cdc.gov/diabetes/data/statistics/statistics-report.html
   Google Scholar
• Piccolo RS, Subramanian SV, Pearce N, et al. Relative contributions of socioeconomic, local environmental, psychosocial, lifestyle/ behavioral,biophysiological, and ancestral factors to racial/ethnic disparities in type 2 diabetes. Diabetes Care. 2016;39:1208‐1217.
   PubMed Web of Science ®Google Scholar
• World Health Organization [Internet]. Global report on diabetes. Geneva, Switzerland: World Health Organization; 2016. cited 2020 Sept 20. Available from https://www.who.int/diabetes/global-report/en/
   Google Scholar